Literature DB >> 2137000

Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding.

U Andersson1, S A Eckernäs, P Hartvig, J Ulin, B Långström, J E Häggström.   

Abstract

Dopamine D2 receptor binding characteristics were studied by positron emission tomography (PET) using N-11C-methyl spiperone as receptor ligand in patients on longterm treatment with neuroleptic drugs and in control subjects. Eight of the patients had symptoms of tardive dyskinesia whereas three patients did not have any symptoms. Control subjects comprised 5 healthy volunteers and 7 patients with pituitary tumors. All patients had been free of neuroleptic drugs for at least 4 weeks. The time dependent regional radioactivity in the striatum was measured and the receptor binding rate, k3, proportional to receptor number, Bmax and association rate for the receptor was calculated in relation to the cerebellum. The lack in difference in k3 values between TD patients, neuroleptic treated patients without TD and control subjects throws doubt on the hypothesis that changes in striatal D2 dopamine receptor number or binding affinity is an etiological mechanism for persistent TD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137000     DOI: 10.1007/bf01245132

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  44 in total

1.  Pharmacology of neuroleptics upon repeated administration.

Authors:  I Moller Nielsen; B Fjalland; V Pedersen; M Nymark
Journal:  Psychopharmacologia       Date:  1974-01-11

2.  Does tardive dyskinesia exist?

Authors:  T J Crow; D G Owens; E C Johnstone; A J Cross; F Owen
Journal:  Mod Probl Pharmacopsychiatry       Date:  1983

3.  An experimental model of tardive dyskinesias.

Authors:  A Clow; P Jenner; C D Marsden
Journal:  Life Sci       Date:  1978-08-07       Impact factor: 5.037

4.  [3H]spiperone binding in the nigrostriatal system in human brain.

Authors:  M Ruberg; B Bokobza; F Javoy-Agid; J C Montfort; Y Agid
Journal:  Eur J Pharmacol       Date:  1984-03-23       Impact factor: 4.432

5.  Dopamine receptor binding in vivo: the feasibility of autoradiographic studies.

Authors:  M J Kuhar; L C Murrin; A T Malouf; N Klemm
Journal:  Life Sci       Date:  1978-01       Impact factor: 5.037

6.  Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration.

Authors:  F Owen; A J Cross; J L Waddington; M Poulter; S J Gamble; T J Crow
Journal:  Life Sci       Date:  1980-01-07       Impact factor: 5.037

7.  Changes in dopamine-mediated behaviour during one year's neuroleptic administration.

Authors:  A Clow; P Jenner; C D Marsden
Journal:  Eur J Pharmacol       Date:  1979-08-15       Impact factor: 4.432

8.  Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia.

Authors:  U Andersson; J E Häggström; E D Levin; U Bondesson; M Valverius; L M Gunne
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

9.  Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesias.

Authors:  L M Gunne; S E Bachus; K Gale
Journal:  Exp Neurol       Date:  1988-06       Impact factor: 5.330

10.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.

Authors:  D F Wong; H N Wagner; L E Tune; R F Dannals; G D Pearlson; J M Links; C A Tamminga; E P Broussolle; H T Ravert; A A Wilson; J K Toung; J Malat; J A Williams; L A O'Tuama; S H Snyder; M J Kuhar; A Gjedde
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

View more
  7 in total

Review 1.  Structural and functional brain imaging in schizophrenia.

Authors:  J M Cleghorn; R B Zipursky; S J List
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

Review 2.  Where have we got to with neuroreceptor mapping of the human brain?

Authors:  B Mazière; M Mazière
Journal:  Eur J Nucl Med       Date:  1990

3.  Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Authors:  H Lublin; J Gerlach; L Peacock
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Authors:  Souha Mahmoudi; Daniel Lévesque; Pierre J Blanchet
Journal:  Mov Disord       Date:  2014-05-16       Impact factor: 10.338

5.  Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol.

Authors:  H Karbe; K Wienhard; K Hamacher; M Huber; K Herholz; H H Coenen; G Stöcklin; A Lövenich; W D Heiss
Journal:  J Neural Transm Gen Sect       Date:  1991

Review 6.  Relevance of animal models to human tardive dyskinesia.

Authors:  Pierre J Blanchet; Marie-Thérèse Parent; Pierre H Rompré; Daniel Lévesque
Journal:  Behav Brain Funct       Date:  2012-03-09       Impact factor: 3.759

Review 7.  Allosteric Interactions between Adenosine A2A and Dopamine D2 Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging.

Authors:  Kavya Prasad; Erik F J de Vries; Philip H Elsinga; Rudi A J O Dierckx; Aren van Waarde
Journal:  Int J Mol Sci       Date:  2021-02-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.